AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals passes US Federal Trade Commission (FTC) audit
AstraZeneca’s proposed acquisition worth $39bn of rare disease treatment organization Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC)
Read more